Drug profile · INN
bimatoprost
DURYSTA
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
bimatoprost (DURYSTA) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
INN bimatoprost
Brand DURYSTA
Route OPHTHALMIC
Formulation SOLUTION
ATC code S01EE03
Originator Amneal Pharma Europe Ltd
Frequently asked questions
What is bimatoprost?
bimatoprost (DURYSTA) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for bimatoprost?
DURYSTA is a marketed brand name for bimatoprost. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bimatoprost?
bimatoprost has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.